Results 231 to 240 of about 50,269 (316)

Exam 2: Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data [PDF]

, 2013

openalex   +1 more source

Does Metabolic Status Associate With IVF Outcomes in Women Within Similar Body Mass Index Category: Evidence From a Large Cohort Study

Journal of Diabetes, Volume 17, Issue 8, August 2025.
The relationship between diverse metabolic statuses within a similar body mass index (BMI) category with different in vitro fertilization (IVF) outcomes. ABSTRACT Objectives Whether diverse metabolic statuses within a similar body mass index (BMI) category associate with different in vitro fertilization (IVF) outcomes.
Lin Ding, Xiaojing Lin, Peipei Pan, Yan Li, Wei Chen, Liying He, Yunsheng Xu, Hsun‐Ming Chang, Haiyan Yang, Guiquan Wang, Liangshan Mu   +10 more
wiley   +1 more source

Liver transplantation in adult polycystic liver disease: the Ontario experience. [PDF]

BMC Gastroenterol, 2021
Alsager M, Neong SF, Gandhi R, Teriaky A, Tang E, Skaro A, Qumosani K, Lilly L, Galvin Z, Selzner N, Bhat MP, Puka K, Brahmania M.   +12 more
europepmc   +1 more source

890 CA19-9 IS A NOVEL BIOMARKER FOR POLYCYSTIC LIVER DISEASE

, 2008
Esmé Waanders, Fred C.G.J. Sweep, Loes van Keimpema, Joost P.H. Drenth   +3 more
openalex   +1 more source

Outcomes of Ultimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A Single‐Center Retrospective Cohort Study

American Journal of Reproductive Immunology, Volume 94, Issue 2, August 2025.
ABSTRACT Problem A proportion of patients with unexplained recurrent implantation failure (uRIF) may have endometrial immune dysregulation amenable to treatment. Ultimpro (Matrice lab Innove, Paris, France) is an endometrial immunophenotype test which identifies the absence or presence and type of immune dysregulation, proposing personalized protocol ...
Genevieve Genest, Alyssa Hochberg, Martine Boivin, Alexie Ferreira, Zhiyang Liu, Coralie Beauchamp, Marc Beltempo, Michael H. Dahan, Elias M. Dahdouh, Ezgi Demirtas, Robert Hemmings, Wael Jamal, Isaac‐Jacques Kadoch, Louise Lapensée, Neal Mahutte, Simon Phillips, Shauna Reinblatt, Camille Sylvestre, William Buckett, Bruce D. Mazer, Ciriaco A. Piccirillo   +20 more
wiley   +1 more source

Polycystic liver disease

, 2012
Mohammad Niknejad, Yuranga Weerakkody
openalex   +2 more sources

NAMPT Overexpression Drives Cell Growth in Polycystic Liver Disease through Mitochondrial Metabolism Regulation. [PDF]

Am J Pathol
Pant K, Gradilone SA.
europepmc   +1 more source

Jaundice in Polycystic Liver Disease: More Than Meets the Eye. [PDF]

Clin Liver Dis (Hoboken), 2021
Brandman D.
europepmc   +1 more source

Feeding Soy Protein Isolate and n-3 PUFA Affects Polycystic Liver Disease Progression in a PCK Rat Model of Autosomal Polycystic Kidney Disease [PDF]

, 2014
Kaitlin Maditz, Vagner A. Benedito, Chris Oldaker, Nainika Nanda, Sundus S. Lateef, Ryan H. Livengood, Janet C. Tou   +6 more
openalex   +1 more source

Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis

Clinical Obesity, Volume 15, Issue 4, August 2025.
Summary The effect of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug–dose combinations of GLP‐1RAs on SBP.
Abraish Ali, Asad Ali Siddiqui, Muhammad Shariq Usman, Izza Shahid, Muhammad Shahzeb Khan, Prinka Perswani   +5 more
wiley   +1 more source